ClinChoice signs up Calyx as preferred provider
ClinChoice has hired ex Parexel tech spinout Calyx as its preferred medical imaging and eClinical solutions provider.
Under the agreement – financial terms of which were not disclosed – Calyx will support the clinical research organization’s (CRO) pharmaceutical, biotechnology, medical device, and consumer product clients.
ClinChoice president Tiepu Liu said, “We chose to partner with Calyx due to their tenured scientific, medical, and technical teams who possess a depth and diversity of experience in providing reliable data outcomes.”
The accord follows a few months after ClinChoice opened a development center in Greater Toronto, Canada.
At the time CEO Ling Zhen said the new center’s proximity to drug developers in North America as key, explaining “The Toronto center will provide us with additional access to top tier talent with close-proximity to many of our clients.
The resources and talents in Canada will join the more than 2200 ClinChoice employees globally and greatly enhance our commitment to delivering quality and efficient research services.”
New contracts
Calyx launched last January following the strategic separation of the Parexel Informatics business from US headquartered CRO Parexel International.
The firm claims to have supported over 25,000 trials involving more than fourteen million patients and has been involved in the development of in excess of 250 new drug products.
News of the ClinChoice deal follows a few weeks after Calyx announced several new contracts. In February, for example, the firm said it had been hired by a “leading pharmaceutical company” to provide to capture real world evidence (RWE) data for a global, late phase study.
Around the same time Calyx announced an extended deal with a “top 20” specialty pharmaceutical company that would see the client use its electronic data capture technology for “multiple additional studies”.
According to Calyx the customer will now use its EDC technology in early phase studies of new compounds being developed for diabetes, obesity, and NASH.
Image: Stock Photo Secrets